TMCI
Treace Medical Concepts Inc
4.40$
+1.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.8% | -3.6% | -6.9% | -5.8% | +2.0% | -5.2% | +0.3% | -4.8% | -3.1% | -3.4% | -1.7% | |
| – | +6.0% | -5.5% | -8.5% | -8.1% | +2.4% | -7.4% | -1.2% | -6.5% | -4.3% | -6.5% | -2.4% | |
| – | +78.4% | -28.1% | +94.8% | -33.4% | -6.3% | +17.8% | -39.8% | -4.5% | +39.3% | -10.9% | +32.1% | |
| – | +0.8% | -10.7% | -13.6% | -12.9% | -8.6% | +0.5% | -8.9% | -17.1% | -15.8% | +7.2% | -12.0% | |
| – | +52.3% | -21.0% | -15.0% | -5.4% | +68.8% | -23.8% | -2.5% | +8.7% | +27.9% | -28.0% | -4.4% | |
| – | -0.2% | +22.6% | +15.1% | +5.6% | -10.0% | -3.3% | +11.7% | -2.3% | -13.0% | +0.9% | +8.7% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -2.6% | -2.6% | -2.7% | -2.8% | -2.9% | -2.9% | -3.0% | -3.1% | -3.2% | -3.3% | -3.4% | |
| – | +11.2% | +2.1% | -2.1% | -5.2% | -3.5% | -3.5% | +8.3% | -1.3% | -3.9% | +3.5% | +6.0% | |
| – | +35.8% | +4.5% | -5.5% | -13.9% | -8.7% | -5.0% | +26.3% | -2.4% | -25.1% | +12.6% | +20.3% | |
| – | +19.2% | -38.5% | -54.5% | +2.5% | +2.5% | +402.7% | +54.3% | +22.2% | – | – | – | |
| – | +36.3% | +78.7% | -14.5% | +3.2% | -43.6% | +25.7% | +50.9% | -19.3% | -58.2% | +101.3% | +18.6% | |
| – | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +3.8% | +0.4% | +0.4% | |
| – | +0.1% | -8.4% | -11.3% | -6.5% | +7.6% | -6.7% | -7.3% | -8.6% | -2.1% | -11.6% | -12.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.2% | +0.2% | +0.5% | +0.2% | +0.2% | +0.5% | +0.6% | +0.8% | +0.5% | +1.1% | +0.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.